Analysis of Debt
Paying user area
Try for free
Allergan Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Geographic Areas
- Common Stock Valuation Ratios
- Enterprise Value (EV)
- Capital Asset Pricing Model (CAPM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Allergan Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Total Debt (Carrying Amount)
Allergan Inc., balance sheet: debt
US$ in thousands
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | ||
|---|---|---|---|---|---|---|
| Notes payable | ||||||
| Convertible notes | ||||||
| Long-term debt, excluding current maturities | ||||||
| Total notes payable and long-term debt (carrying amount) |
Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).
| Debt item | Description | The company |
|---|---|---|
| Total notes payable and long-term debt (carrying amount) | Sum of the carrying values as of the balance sheet date of all debt plus capital lease obligations. | Allergan Inc. total debt increased from 2012 to 2013 and from 2013 to 2014. |
Total Debt (Fair Value)
| Dec 31, 2014 | |
|---|---|
| Selected Financial Data (US$ in thousands) | |
| Notes payable | |
| Convertible notes | |
| Long-term debt | |
| Total notes payable and long-term debt (fair value) | |
| Financial Ratio | |
| Debt, fair value to carrying amount ratio | |
Based on: 10-K (reporting date: 2014-12-31).
Weighted-average Interest Rate on Debt
Weighted-average effective interest rate on debt:
| Interest rate | Debt amount1 | Interest rate × Debt amount | Weighted-average interest rate2 |
|---|---|---|---|
| Total | |||
Based on: 10-K (reporting date: 2014-12-31).
1 US$ in thousands
2 Weighted-average interest rate = 100 × ÷ =
Interest Costs Incurred
Allergan Inc., interest costs incurred
US$ in thousands
| 12 months ended: | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest expense | |||||||||||
| Interest capitalized | |||||||||||
| Interest costs incurred |
Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).
| Debt item | Description | The company |
|---|---|---|
| Interest expense | Amount of the cost of borrowed funds accounted for as interest expense for debt. | Allergan Inc. interest expense increased from 2012 to 2013 but then slightly decreased from 2013 to 2014. |
| Interest capitalized | Amount of interest costs capitalized disclosed as an adjusting item to interest costs incurred. | Allergan Inc. interest capitalized increased from 2012 to 2013 and from 2013 to 2014. |
| Interest costs incurred | Total interest costs incurred during the period and either capitalized or charged against earnings. | Allergan Inc. interest costs incurred increased from 2012 to 2013 but then slightly decreased from 2013 to 2014. |
Adjusted Interest Coverage Ratio
Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).
2014 Calculations
1 Interest coverage ratio (without capitalized interest) = EBIT ÷ Interest expense
= ÷ =
2 Adjusted interest coverage ratio (with capitalized interest) = EBIT ÷ Interest costs incurred
= ÷ =
| Solvency ratio | Description | The company |
|---|---|---|
| Adjusted interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments (including capitalized interest). | Allergan Inc. adjusted interest coverage ratio deteriorated from 2012 to 2013 but then improved from 2013 to 2014 exceeding 2012 level. |